Skip to main content
Erschienen in: Journal of Neurology 10/2016

08.07.2016 | Original Communication

Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ)

verfasst von: Tjalf Ziemssen, Glenn Phillips, Ruchit Shah, Adam Mathias, Catherine Foley, Cheryl Coon, Rohini Sen, Andrew Lee, Sonalee Agarwal

Erschienen in: Journal of Neurology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

The Early Mobility Impairment Questionnaire (EMIQ) was developed to facilitate early identification of mobility impairments in multiple sclerosis (MS) patients. We describe the initial development of the EMIQ with a focus on the psychometric evaluation of the questionnaire using classical and item response theory methods. The initial 20-item EMIQ was constructed by clinical specialists and qualitatively tested among people with MS and physicians via cognitive interviews. Data from an observational study was used to make additional updates to the instrument based on exploratory factor analysis (EFA) and item response theory (IRT) analysis, and psychometric analyses were performed to evaluate the reliability and validity of the final instrument’s scores and screening properties (i.e., sensitivity and specificity). Based on qualitative interview analyses, a revised 15-item EMIQ was included in the observational study. EFA, IRT and item-to-item correlation analyses revealed redundant items which were removed leading to the final nine-item EMIQ. The nine-item EMIQ performed well with respect to: test–retest reliability (ICC = 0.858); internal consistency (α = 0.893); convergent validity; and known-groups methods for construct validity. A cut-point of 41 on the 0-to-100 scale resulted in sufficient sensitivity and specificity statistics for viably identifying patients with mobility impairment. The EMIQ is a content valid and psychometrically sound instrument for capturing MS patients’ experience with mobility impairments in a clinical practice setting. Additional research is suggested to further confirm the EMIQ’s screening properties over time.
Literatur
2.
Zurück zum Zitat Kingwell E, Marriott JJ, Jette N, Pringsheim T, Makhani N, Morrow SA, Fisk JD, Evans C, Beland SG, Kulaga S, Dykeman J, Wolfson C, Koch MW, Marrie RA (2013) Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 13:128CrossRefPubMedPubMedCentral Kingwell E, Marriott JJ, Jette N, Pringsheim T, Makhani N, Morrow SA, Fisk JD, Evans C, Beland SG, Kulaga S, Dykeman J, Wolfson C, Koch MW, Marrie RA (2013) Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 13:128CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Janzen W, Turpin KV, Warren SA, Marrie RA, Warren KG (2013) Change in the health-related quality of life of multiple sclerosis patients over 5 years. Int J MS Care 15:46–53CrossRefPubMedPubMedCentral Janzen W, Turpin KV, Warren SA, Marrie RA, Warren KG (2013) Change in the health-related quality of life of multiple sclerosis patients over 5 years. Int J MS Care 15:46–53CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Buhse M, Banker WM, Clement LM (2014) Factors associated with health-related quality of life among older people with multiple sclerosis. Int J MS Care 16:10–19CrossRefPubMedPubMedCentral Buhse M, Banker WM, Clement LM (2014) Factors associated with health-related quality of life among older people with multiple sclerosis. Int J MS Care 16:10–19CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat van Asch P (2011) Impact of mobility impairment in multiple sclerosis 2—patients’ perspectives. European Neurological Review 6:115–120CrossRef van Asch P (2011) Impact of mobility impairment in multiple sclerosis 2—patients’ perspectives. European Neurological Review 6:115–120CrossRef
6.
Zurück zum Zitat Krause I, Kern S, Horntrich A, Ziemssen T (2013) Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. Mult Scler 9(13):1792–1799. doi:10.1177/1352458513485655 CrossRef Krause I, Kern S, Horntrich A, Ziemssen T (2013) Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. Mult Scler 9(13):1792–1799. doi:10.​1177/​1352458513485655​ CrossRef
7.
Zurück zum Zitat Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582CrossRefPubMed Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582CrossRefPubMed
8.
Zurück zum Zitat Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904CrossRefPubMed Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898–904CrossRefPubMed
9.
Zurück zum Zitat Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radu EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8:987–997CrossRefPubMed Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radu EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8:987–997CrossRefPubMed
10.
Zurück zum Zitat Kinkel RP, Kiollman C, O’Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horoqitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Sehorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66:678–684CrossRefPubMed Kinkel RP, Kiollman C, O’Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horoqitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Sehorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66:678–684CrossRefPubMed
11.
Zurück zum Zitat Martin CL, Phillips BA, Kilpatrick TJ, Butzkueven H, Tubridy N, McDonald E, Galea MP (2006) Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 12:620–628CrossRefPubMed Martin CL, Phillips BA, Kilpatrick TJ, Butzkueven H, Tubridy N, McDonald E, Galea MP (2006) Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler 12:620–628CrossRefPubMed
12.
Zurück zum Zitat Swingler RJ, Compston DA (1992) The morbidity of multiple sclerosis. Q J Med 83:325–337PubMed Swingler RJ, Compston DA (1992) The morbidity of multiple sclerosis. Q J Med 83:325–337PubMed
13.
Zurück zum Zitat LaRocca NG (2011) Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient 4:189–201CrossRefPubMed LaRocca NG (2011) Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners. Patient 4:189–201CrossRefPubMed
14.
Zurück zum Zitat World Health Organization (2007) Internationl classification of functioning, disability and health: children and youth version: ICF-CY. World Health Organization, Geneva World Health Organization (2007) Internationl classification of functioning, disability and health: children and youth version: ICF-CY. World Health Organization, Geneva
15.
Zurück zum Zitat Anderseck B, van Asch P, Johnson J, Agarwal S, Hudgens S, Humphrey L, Medcalf R, Ziemssen T (2013) Early mobility impairment: bridging the communication gap between people with multiple sclerosis and their healthcare providers. Presented at 23rd Meeting of the European Neurological Society, Barcelona, Spain Anderseck B, van Asch P, Johnson J, Agarwal S, Hudgens S, Humphrey L, Medcalf R, Ziemssen T (2013) Early mobility impairment: bridging the communication gap between people with multiple sclerosis and their healthcare providers. Presented at 23rd Meeting of the European Neurological Society, Barcelona, Spain
16.
Zurück zum Zitat Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452CrossRefPubMed Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452CrossRefPubMed
17.
Zurück zum Zitat Hohol MJ, Orav EJ, Weiner HL (1999) Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler 5:349–354CrossRefPubMed Hohol MJ, Orav EJ, Weiner HL (1999) Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler 5:349–354CrossRefPubMed
18.
Zurück zum Zitat Hohol MJ, Orav EJ, Weiner HL (1995) Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 45:251–255CrossRefPubMed Hohol MJ, Orav EJ, Weiner HL (1995) Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 45:251–255CrossRefPubMed
19.
Zurück zum Zitat Marrie RA, Goldman M (2007) Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler 13:1176–1182CrossRefPubMed Marrie RA, Goldman M (2007) Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler 13:1176–1182CrossRefPubMed
20.
Zurück zum Zitat The EuroQol Group (1990) EuroQol-5D: a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef The EuroQol Group (1990) EuroQol-5D: a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef
21.
Zurück zum Zitat Hobart J, Riazi A, Lamping R (2003) Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12). Am Acad Neurol 60:31–36 Hobart J, Riazi A, Lamping R (2003) Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12). Am Acad Neurol 60:31–36
22.
Zurück zum Zitat Muthén LK, Muthén BO (2004) Mplus user’s guide, 3rd edn. Muthén & Muthén, Los Angeles Muthén LK, Muthén BO (2004) Mplus user’s guide, 3rd edn. Muthén & Muthén, Los Angeles
23.
Zurück zum Zitat Cai L, Du Toit SHC, Thissen D (2012) IRTPRO: flexible, multidimensional, multiple categorical IRT modeling. [Scientific Software]. Scientific Software International, International Lincolnwood, IL Cai L, Du Toit SHC, Thissen D (2012) IRTPRO: flexible, multidimensional, multiple categorical IRT modeling. [Scientific Software]. Scientific Software International, International Lincolnwood, IL
24.
Zurück zum Zitat Gliem JA, Gliem RR (2003) Calculating, interpreting, and reporting Cronbach’s alpha reliability coefficient for Likert-type scales. Presented at Midwest Research-to-Practice Conference in Adult, Continuing, and Community Education, Columbus, OH Gliem JA, Gliem RR (2003) Calculating, interpreting, and reporting Cronbach’s alpha reliability coefficient for Likert-type scales. Presented at Midwest Research-to-Practice Conference in Adult, Continuing, and Community Education, Columbus, OH
25.
Zurück zum Zitat Pompilus F, Burgess S, Hudgens S, Banderas B, Daniels S (2015) Development and validation of a novel patient-reported treatment satisfaction measure for hyperfunctional facial lines: facial line satisfaction questionnaire. J Cosmet Dermatol. 14(4):274–285. doi:10.1111/jocd.12166 CrossRefPubMed Pompilus F, Burgess S, Hudgens S, Banderas B, Daniels S (2015) Development and validation of a novel patient-reported treatment satisfaction measure for hyperfunctional facial lines: facial line satisfaction questionnaire. J Cosmet Dermatol. 14(4):274–285. doi:10.​1111/​jocd.​12166 CrossRefPubMed
26.
Zurück zum Zitat Aday LA (1996) Designing and conducting health surveys: a comprehensive guide. Jossey-Bass, San Francisco Aday LA (1996) Designing and conducting health surveys: a comprehensive guide. Jossey-Bass, San Francisco
27.
Zurück zum Zitat Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334CrossRef Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334CrossRef
28.
Zurück zum Zitat Nunnally JC, Bernstein I (1994) The assessment of reliability. Psychometric theory, 3rd edn. McGraw Hill, New York. pp 248–292 Nunnally JC, Bernstein I (1994) The assessment of reliability. Psychometric theory, 3rd edn. McGraw Hill, New York. pp 248–292
29.
Zurück zum Zitat Fayers P, Machin D (2000) Quality of life: assessment, analysis, and interpretation. Wiley and Sons, West SussexCrossRef Fayers P, Machin D (2000) Quality of life: assessment, analysis, and interpretation. Wiley and Sons, West SussexCrossRef
30.
Zurück zum Zitat Schumacker RE, Lomax RG (1996) A beginner’s guide to structural equation modeling. Lawrence Erlbaum Associates, Mahwah Schumacker RE, Lomax RG (1996) A beginner’s guide to structural equation modeling. Lawrence Erlbaum Associates, Mahwah
31.
Zurück zum Zitat MacCallum RC, Browne MW, Sugawara HM (1996) Power analysis and determination of sample size for covariance structure modeling. In: Psychological methods, 1 edn. pp 130–149 MacCallum RC, Browne MW, Sugawara HM (1996) Power analysis and determination of sample size for covariance structure modeling. In: Psychological methods, 1 edn. pp 130–149
32.
Zurück zum Zitat Kaiser HF (1960) The application of electronic computers to factor analysis. Educ Psychol Measur 20:141–151CrossRef Kaiser HF (1960) The application of electronic computers to factor analysis. Educ Psychol Measur 20:141–151CrossRef
33.
Zurück zum Zitat Bates D, Burks J, Globe D, Signori M, Hudgens S, Denys P, MacDiarmid S, Nitti V, Odderson I, Ross AP, Chancellor M (2013) Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool. BMC Neurol 13:78CrossRefPubMedPubMedCentral Bates D, Burks J, Globe D, Signori M, Hudgens S, Denys P, MacDiarmid S, Nitti V, Odderson I, Ross AP, Chancellor M (2013) Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool. BMC Neurol 13:78CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Hu L, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model 6:1–55CrossRef Hu L, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model 6:1–55CrossRef
35.
Zurück zum Zitat Browne MW, Cudeck R (1993) Alternative ways of assessing model fit. In: Bollen KA, Long JS (eds) Testing structural equation models. Sage, Newbury Park, pp 136–162 Browne MW, Cudeck R (1993) Alternative ways of assessing model fit. In: Bollen KA, Long JS (eds) Testing structural equation models. Sage, Newbury Park, pp 136–162
36.
Zurück zum Zitat Coon CD, Williams VSL, Nelson LM, Price MA. Determining missing data rules for Patient-Reported Outcomes: Alpha-if-item-deleted. 2010. ISPOR 15th Annual International Meeting Coon CD, Williams VSL, Nelson LM, Price MA. Determining missing data rules for Patient-Reported Outcomes: Alpha-if-item-deleted. 2010. ISPOR 15th Annual International Meeting
38.
Zurück zum Zitat Kalron A, Nitzani D, Magalashvili D, Dolev M, Menascu S, Stern Y, Rosenblum U, Pasitselsky D, Frid L, Zeilig G, Barmatz C, Givon U, Achiron A (2015) A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort. BMC Neurol 15:21CrossRefPubMedPubMedCentral Kalron A, Nitzani D, Magalashvili D, Dolev M, Menascu S, Stern Y, Rosenblum U, Pasitselsky D, Frid L, Zeilig G, Barmatz C, Givon U, Achiron A (2015) A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort. BMC Neurol 15:21CrossRefPubMedPubMedCentral
Metadaten
Titel
Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ)
verfasst von
Tjalf Ziemssen
Glenn Phillips
Ruchit Shah
Adam Mathias
Catherine Foley
Cheryl Coon
Rohini Sen
Andrew Lee
Sonalee Agarwal
Publikationsdatum
08.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 10/2016
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-016-8210-4

Weitere Artikel der Ausgabe 10/2016

Journal of Neurology 10/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

03.05.2024 Parkinson-Krankheit Nachrichten

Kann eine frühzeitige Stuhltransplantation das Fortschreiten von Parkinson-Symptomen verlangsamen? Die Ergebnisse einer randomisierten Phase-2-Studie scheinen dafür zu sprechen.

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

02.05.2024 Hirnblutung Nachrichten

Erhalten Personen mit einer spontanen Hirnblutung innerhalb von zwei Stunden nach Symptombeginn eine Tranexamsäure-Therapie, kann dies weder die Hämatomexpansion eindämmen noch die Mortalität senken.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.